Posts

TKO Which Way You Gonna Go?

TKO: Constructive Test of Resistance on Light Volume (June 24, 2026) TKO: Constructive Test of Resistance on Light Volume (June 24, 2026) Posted: June 24, 2026 I’ve been watching TKO (TKO Group Holdings — the UFC/WWE parent) today and it’s a clean example of something I see fairly often in swing setups: price making a decent push into resistance while volume stays conspicuously quiet. Today’s Numbers (as of \~2:00 PM CDT) Previous close: 202.70 Open: \~203.52–203.58 Day high: 206.75 Current price: \~205.4–205.7 (+1.3–1.4%) Volume: \~350K–540K vs \~1.5–2.0M average That’s roughly 25–35% of normal daily volume. The stock is holding above the open, tagging the upper end of the day’s range, and putting in a solid green day. On the surface it looks constructive. What Stands Out Bullish Trading well above the open Making a higher high and holding near session highs Positive momentum (+1.3%+) Sitting right at the lower edge of the resista...

OUCH Grok API

💡 Is the Grok API Worth It? The Grok API can be incredibly powerful, and you can get a tremendous amount of work done in a very short period of time. It's honestly hard to argue that it isn't worth the cost. That said, I've learned that sloppy prompting costs extra tokens . Here are a few simple ways to reduce token usage: Use shorter, more direct prompts. Skip unnecessary words like "please" and "thank you." Avoid running the same report repeatedly. Build in fail-safes to prevent duplicate requests. Be intentional and efficient with your prompts. A little optimization can save you a surprising number of tokens over time. Overall, if you're smart about how you use it, the Grok API can be an excellent value and a huge productivity booster. ☕ Support My Work If you find this content valuable and it has saved you time or money, please consider supporting me on Ko-fi. Every contribution helps me continue creating useful cont...

Stock explodes! Here's why!

Why the News Always Seems Late to the Market One of the observations that repeatedly changed the way I look at markets was noticing how often stocks moved before any explanation appeared. A stock would break out on heavy volume, a sector would suddenly catch a bid, or a major index would reverse sharply, yet there would be no obvious headline explaining the move. Hours later, the financial media would publish a story assigning a reason to the price action. The explanation might sound convincing, but the timing often raises an important question: was the news driving the move, or was the news simply explaining a move that had already happened? The Anatomy of the Lagging Narrative Every active trader has experienced the comedy of watching a clean technical breakout or breakdown trigger perfectly on price, volume, and order flow, only for the financial media to remain completely silent. Then, two hours later, the "breaking news" alert drops to retroactively assign a n...

AXTI — Oops old article didn't publish in the right place

AXTI Swing Trading Playbook - May 28, 2026 Current Price Range ~$115 – $117 ▲ Volatile Previous Close $115.70 Assessment Date May 28, 2026 AXT Inc. (AXTI) is a specialty materials company that manufactures compound semiconductor substrates, primarily indium phosphide (InP), gallium arsenide (GaAs), and germanium wafers. These materials are essential for high-growth sectors including AI data centers, 5G/6G infrastructure, optical networking, LEDs, and solar cells. The company is aggressively expanding InP production capacity to capitalize on surging AI demand. Swing Trade Scenarios & Risk Profiles Scenario Entry Point Stop-Loss Target(s) Potential Return R:R Ratio Est. Prob. Strategic Notes Bullish Pullback Buy...

PIII Technical Swing Trade: Oversold Bounce Setup Emerges at Key Support

PIII Technical Swing Trade: Oversold Bounce Setup Emerges at Key Support PIII Technical Swing Trade: Oversold Bounce Setup Emerges at Key Support Published: June 23, 2026 • Personal Trading Playbook 48/100 Conviction Score 1:2.6 Risk / Reward +47.0% Expected Value 1–2% Suggested Alloc. AI Execution Summary: P3 Health Partners (PIII) reported a strong Q1 2026 turnaround with $25.8 million adjusted EBITDA and raised full-year guidance to $20-60 million EBITDA on $1.5-1.65 billion revenue, shifting from prior losses to profitability signals in its Medicare Advantage value-based care model. Combined with the stock's sharp pullback to the $10.75 area on June 18, 2026, and RSI nearing oversold levels around 33, this creates a compelling technical swing setup for a bounce toward $11.80 and $14.00 analyst targets. The physician-led population health platform posi...

NRDS Swing Setup: Neutral RSI at $8.59 Creates Measured Long Opportunity with Strong Asymmetry

NRDS Swing Setup: Neutral RSI at $8.59 Creates Measured Long Opportunity with Strong Asymmetry NRDS Swing Setup: Neutral RSI at $8.59 Creates Measured Long Opportunity with Strong Asymmetry Published: June 23, 2026 • Personal Trading Playbook 61/100 Conviction Score 1:4.3 Risk / Reward +10.4% Expected Value 2–3% Suggested Alloc. AI Execution Summary: NRDS presents a moderate-conviction long swing setup with an attractive asymmetric risk-to-reward edge of 1:4.3. Price action has stabilized just above the critical $8.20-8.34 support shelf while RSI remains neutral near 51, suggesting room for upside without immediate overbought conditions. Timing is favorable with the stock trading only 0.5-1.6% above the planned structural entry zone of $8.45-8.55 on June 22, 2026, allowing for a disciplined reload on any minor dip. The setup is supported by analyst price targ...

QH Stock: High-Volume Momentum Breakout Sets Up Aggressive Swing Long Opportunity

QH Stock: High-Volume Momentum Breakout Sets Up Aggressive Swing Long Opportunity QH Stock: High-Volume Momentum Breakout Sets Up Aggressive Swing Long Opportunity Published: June 23, 2026 • Personal Trading Playbook 33/100 Conviction Score 1:1.5 Risk / Reward +32.3% Expected Value 0–0.5% Suggested Alloc. AI Execution Summary: QH presents a cautious-conviction speculative profile with an asymmetric but low-probability risk-to-reward edge of roughly 1:1.8. Price has broken sharply below key short-term EMAs on heavy volume with RSI at approximately 37.6, signaling weakening momentum in a strong downtrend. Timing is poor as the live price sits well below the planned entry zone near $8.00-8.50, offering no immediate structural reload opportunity without further stabilization or catalyst-driven reversal. Trade Execution Matrix ...

ACHV Swing Trade Setup: Late-Stage Pipeline Centered on Cytisinicline for Nicotine Dependence

ACHV Swing Trade Setup: Post-Breakdown Reversal Opportunity or Wait-and-See? ACHV Swing Trade Setup: Post-Breakdown Reversal Opportunity or Wait-and-See? Published: June 23, 2026 • Personal Trading Playbook 59/100 Conviction Score 1:1.2 Risk / Reward +11.8% Expected Value 2–3% Suggested Alloc. AI Execution Summary: ACHV presents a moderate-conviction technical swing setup with an asymmetric risk-to-reward edge of 1:1.8. Price action has rebounded sharply from oversold RSI levels on elevated volume following the June 20, 2026 PDUFA outcome, with the stock trading just 0-2% above the planned structural entry zone near $5.00-5.10 as of June 23, 2026. The key catalyst remains the company's plan to address the FDA's manufacturing-related Complete Response Letter with a targeted Q4 resubmission, positioning cytisinicline for potential approval as the first ...

Sector Rotation Biotech Up

How This Ended Up On My Radar I wasn't actively looking for a biotech rotation. What caught my attention was something much simpler: several healthcare and biotech names on my watchlists were holding up surprisingly well while many technology names were seeing profit taking. When individual stocks start acting differently than the broader market, I pay attention. A few isolated names can be random. Multiple names showing relative strength at the same time often signals something larger happening beneath the surface. After seeing repeated strength across several healthcare and biotech setups, I started digging deeper. That's when the pieces began lining up: institutional money rotating out of crowded technology trades, a major biotech acquisition, a successful IPO, and improving action across the broader group. The sector didn't become interesting because of a headline. The headlines helped explain what the charts were already starting to show. The market just handed u...

DFTX Weak, But Still Interesting

DFTX — Weak swing playbook DFTX — Weak swing playbook Published: June 22, 2026 • Personal Trading Playbook 45/100 Conviction Score 1:2.3 Risk / Reward +23.2% Expected Value 1–2% Suggested Alloc. AI Execution Summary: DFTX presents a moderate-conviction swing setup featuring an asymmetric risk-to-reward edge of 1:2.3. Price action has reclaimed key moving averages on the back of the June 22 Phase 3 catalyst while remaining only 3-6% above the planned structural reload zone at $34.50-35.50. Timing is highly optimized with the stock consolidating near the new high-volume node after the parabolic gap, allowing disciplined entries on any modest dip rather than chasing the initial surge. Trade Execution Matrix Trade Scenario Entry Trigger Exit / Target Point Return Profile Probability ...

VRDN

VRDN Swing Trade Setup: Neutral RSI Pullback Offers Measured Long Opportunity on June 22, 2026 VRDN Swing Trade Setup: Neutral RSI Pullback Offers Measured Long Opportunity on June 22, 2026 Published: June 22, 2026 • Personal Trading Playbook 56/100 Conviction Score 1:2 Risk / Reward +5.5% Expected Value 1–2% Suggested Alloc. AI Execution Summary: Viridian Therapeutics (VRDN) stands at a pivotal inflection point on June 22, 2026, with its lead asset veligrotug (VRDN-001) under FDA Priority Review and a PDUFA target action date of June 30, 2026-just eight days away. The stock trades near $16.63 after a modest pullback on elevated volume, creating a compelling technical setup for a catalyst-driven swing. Positive Phase 3 data from THRIVE and THRIVE-2 in active and chronic thyroid eye disease (TED) support a potential approval that could unlock significant upsid...

ELF

June 22, 2026 Personal Trading Playbook ELF Beauty (NYSE: ELF) Neutral RSI & Short-Term Support Create Measured Swing Opportunity at $62-63 Risk Disclaimer: This analysis is for educational and informational purposes only and does not constitute financial, investment, or trading advice. Trading involves substantial risk of loss. Only risk capital you can afford to lose. Past performance is not indicative of future results. Executive Summary Live Reference $62.24 Session Change -3.05% Daily Volume 1,476,759 Core Catalyst Overview e.l.f. Beauty operates exclusively in cosmetics and skincare (no medical PDUFA tracks). Core intermediate drivers feature its Fall 2026 milestone pipeline innovation drops paired with rhode's high-profile commercial launch across 19 European Sephora markets, driving incremental international numb...